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ABSTRACT
Muscleblind-like 1 (MBNL1) regulates alternative
splicing and is a key player in the disease mecha-
nism of myotonic dystrophy (DM). In DM, MBNL1
becomes sequestered to expanded CUG/CCUG
repeat RNAs resulting in splicing defects, which
lead to disease symptoms. In order to understand
MBNL1’s role in both the disease mechanism of DM
and alternative splicing regulation, we sought to
identify its RNA-binding motif. A doped SELEX was
performed on a known MBNL1-binding site. After
five rounds of SELEX, MBNL1 selected
pyrimidine-rich RNAs containing YGCY motifs.
Insertion of multiple YGCY motifs into a normally
MBNL1-independent splicing reporter was sufficient
to promote regulation by MBNL1. MBNL1 was also
shown to regulate the splicing of exon 22 in the
ATP2A1 pre-mRNA, an exon mis-spliced in DM, via
YGCY motifs. A search for YGCY motifs in 24
pre-mRNA transcripts that are mis-spliced in DM1
patients revealed an interesting pattern relative to
the regulated exon. The intronic regions upstream
of exons that are excluded in normal tissues relative
to DM1, are enriched in YGCY motifs. Meanwhile,
the intronic regions downstream of exons that are
included in normal tissues relative to DM1,
are enriched in YGCY motifs.
INTRODUCTION
Alternative splicing is essential for creating a diverse and
functional proteome as well as for establishing tissue and
developmentally speciﬁc repertoires of mRNAs. It has
been shown that  90% of human pre-mRNAs are
alternatively spliced (1). Several proteins [e.g. NOVA1,
CUGBP1, MBNL1, A2BP1 (also known as Fox-1) and
their related paralogs] have been shown to play important
roles in the regulation of alternative splicing (2–4).
NOVA1 is a neuron-speciﬁc regulator of alternative
splicing that binds YCAY clusters in or near alternatively
spliced exons and promotes exon inclusion or exclusion,
depending on the location of the binding site (3,5). A2BP1
is expressed in brain, heart and skeletal muscle and binds
the UGCAUG RNA motif (6). Based on hundreds of pre-
dicted A2BP1-binding sites, A2BP1 binding upstream of
the regulated exon promotes exclusion while binding
downstream promotes inclusion (4). Although much less
is known about MBNL1-binding sites, a similar model of
alternative splicing regulation has been proposed for the
MBNL1 proteins (2,7).
The original member of the muscleblind family of
proteins, muscleblind (Mbl) was identiﬁed in Drosophila
and found to be important in photoreceptor and muscle
diﬀerentiation (8,9). The orthologous proteins,
muscleblind-like 1–3 (MBNL1, MBNL2 and MBNL3)
were discovered in humans as the proteins sequestered
to the toxic CUG and CCUG repeats that cause
mytonic dystrophies 1 and 2 (DM1 and DM2), respec-
tively (10–13). The muscleblind proteins are generally
highly conserved, especially in the zinc ﬁnger domains,
and bind RNA in a speciﬁc fashion through these
domains (7,14–17). The sequestration of MBNL results
in its lack of binding to normal pre-mRNA targets. This
lack of binding by MBNL causes important developmen-
tally speciﬁc transcripts to become mis-spliced and leads
to symptoms of DM (for reviews see 13,18,19). For
example, insulin receptor (INSR) and chloride ion
channel (CLCN1) pre-mRNAs are mis-spliced in DM1
patients leading to inappropriate expression of fetal
isoforms and/or degradation of the transcript (20–22).
The lack of appropriate INSR and CLCN1 splice
isoforms in DM1 patients is thought to lead to the
symptoms of insulin resistance and myotonia, respectively.
MBNL1 promotes the exclusion of exon 5 in the
TNNT2 (also known as cTNT) pre-mRNA, which
produces a splice product found in adult tissue.
However, in DM1, exon 5 is included aberrantly, thus
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(23). It has now been shown that the sequestration of
MBNL1 and MBNL2 is responsible for this mis-splicing
(24). MBNL1 binds a 32-nucleotide region upstream of
exon 5 and regulates splicing through this site (7,24,25).
In addition to TNNT2, several other pre-mRNA tran-
scripts are regulated by MBNL1, including ATP2A1
(also known as SERCA1), and auto-regulation of
MBNL1 and MBNL2 pre-mRNAs (for reviews see
13,19). The only previously characterized
MBNL1-binding site in a human pre-mRNA is the
32-nucleotide TNNT2 site. The identiﬁcation of addi-
tional MBNL1 RNA-binding sites would allow for a
deeper understanding of MBNL1’s RNA-binding
speciﬁcity. This will help determine pre-mRNA targets
regulated by MBNL1 and to predict MBNL1-binding
sites within these targets.
We performed a doped SELEX (Systematic Evolution
of Ligands by Exponential Enrichment) experiment, using
the TNNT2-binding site as a template, to identify
sequences that MBNL1 binds with high aﬃnity. The
doping incorporated the endogenous binding site
nucleotides at a rate of 51% for each of the 32 residue
positions. The majority of sequences recovered after ﬁve
rounds of selection bound MBNL1 with an aﬃnity similar
to MBNL1’s aﬃnity for the native TNNT2 site. We
observed that there was a general selection for pyrim-
idines and a speciﬁc selection for the motif YGCY. We
showed that placing multiple YGCY motifs in a splicing
reporter minigene, which was not previously regulated by
MBNL1, was suﬃcient for MBNL1-dependent splicing
regulation. We analyzed the sequences surrounding
cassette exons in 24 pre-mRNAs that are mis-regulated
in DM1 patients and identiﬁed over 100 YGCY potential
MBNL1-binding sites. We then demonstrated that
MBNL1 binds with high aﬃnity to RNA oligomers
derived from several of these endogenous YGCY motifs.
We also showed that multiple YGCY instances
signiﬁcantly contribute to MBNL1 regulated splicing of
an ATP2A1 exon known to be mis-spliced in DM1. And
ﬁnally, we observed that YGCY motifs are enriched in the
intronic regions upstream of cassette exons that are
normally excluded (aberrantly included in DM1), and,
conversely, are enriched downstream of exons that are
normally included (aberrantly excluded in DM1).
Together, these results aid in deﬁning MBNL1’s RNA-
binding speciﬁcity, which will ultimately help lead to the
identiﬁcation of more MBNL1 endogenous binding sites
and provide a better understanding of the mechanisms by
which MBNL1 regulates splicing.
MATERIALS AND METHODS
SELEX
The MBNL1 expression construct included residues 1–260
and contains an N-terminal GST tag. This construct,
termed MBNL1 throughout the article, binds RNA as
tightlyas thefull-length version (7).MBNL1was expressed
and puriﬁed as described earlier (7). The DNA template
used for the SELEX (26) experiment was the following
81-mer oligonucleotide: 50-GGGAATGGATCCACATC
TACGAATTC(CCTGTCTCGCTTTTCCCCTCCGCT
GCGGCCAC)AAGACTCGATACGTGACGAACC
T-3.0 The oligonucleotide depicted here contains the
32-nucleotide MBNL1-binding site in TNNT2 (in paren-
thesis) ﬂanked by two constant regions. To create SELEX
pool 0, the nucleotides in parenthesis were randomized;
51% of the time the original nucleotide was kept at each
position and the other 49% of the time each position was
varied to incorporate an equal mix of the other three
nucleotides. The forward primer for the SELEX was 50-G
ATAATACGACTCACTATAGGGAATGGATCCACA
TCTACGA-30 (including a T7 RNA polymerase site for
in vitro transcription) and the reverse was 50-AGGTTCG
TCACGTATCGAGTCTT-30. The initial PCR reaction
was ampliﬁed by eight rounds of PCR and 1 10
14 DNA
molecules from the PCR reaction were used for the initial
transcription reaction. The transcription reactions were
done under the following conditions: 500ng/ml template,
40mM Tris pH 7.9, 26mM MgCl2, 2mM spermidine,
10mM NaCl, 5mM of each nucleotide, 0.1mg/100ml
yeast pyrophosphatase,  2mg/ml T7 polymerase and
40mM DTT. The transcription reactions were performed
with trace amounts of [a-P
32] cytidine triphosphate (CTP)
for monitoring purposes. After transcription, reactions
were treated with DNase for 1h at 37 C, gel puriﬁed and
ethanol precipitated. For each round, the appropriate con-
centration of MBNL1 (see below) was bound to 20mlo f
glutathione-agarose beads at 4 C for 15min, then washed
once with 200ml of SELEX-binding buﬀer (100mM NaCl,
20mM Tris pH 7.5, 5mM MgCl2, 0.02% Triton X-100 and
5mM DTT added the day of use). All washes were done in
a similar manner. The RNA was heated in SELEX-binding
buﬀer at 95 C for 3min and placed immediately on ice for
10min. The MBNL1-bound beads were incubated with the
annealed RNA at 25 C for 20min. The beads were washed
once with 200ml of SELEX binding buﬀer at 25 C and
RNA was released and collected from the beads by
a phenol–chloroform extraction and subsequent ethanol
precipitation. The binding conditions were chosen such
that 5–10% of the RNA was retained after each round.
The collected RNA was reverse transcribed using
Avian Myeloblastosis Virus (AMV) reverse transcriptase,
1 AMV buﬀer, 8.8mM reverse primer, and two-third of
the RNA isolated after the round for 1h at 42 C. After the
reversetranscriptionwascomplete,theDNAwasampliﬁed
by 11 PCR cycles. The DNA was transcribed and the
SELEX cycle repeated a total of ﬁve times with the concen-
tration of RNA and MBNL1 varying. The concentrations
of RNA and MBNL1 used were as follows: Round 1
(20mM RNA, 20mM MBNL1), Round 2 (9.8mM RNA,
4.9mM MBNL1), Round 3 (8mM RNA, 2mM MBNL1),
Round 4 (2mM RNA, 0.33mM MBNL1), Round 5 (1mM
RNA, 0.13mM MBNL1). After ﬁve rounds were
completed, individual clones were isolated by TOPO
cloning (Invitrogen) and sequenced.
Labeling of RNAs for gel mobility shift assays
SELEX RNA oligonucleotides were transcribed from
DNA templates using T7 RNA polymerase and [a-P
32]
2468 Nucleic Acids Research, 2010,Vol.38, No. 7CTP. Commercially purchased RNA oligonu-
cleotides were kinased using Polynucleotide Kinase and
[g-P
32] ATP.
Gel mobility shift assay
Gel mobility shift assays and Kd calculations were
performed as described earlier (7), with the following
modiﬁcations. RNA (8ml) was snap annealed in (75mM
NaCl, 5mM MgCl2, 15mM Tris pH 7.5, 0.25mM b-ME),
then mixed with 2ml of protein for ﬁnal reaction condi-
tions of 175mM NaCl, 5mM MgCl2, 20mM Tris pH 7.5,
1.25mM b-ME, 10% glycerol, 2mg/ml BSA, 0.1mg/ml
heparin and trace amounts of bromophenol blue. The
binding reactions were incubated for 10–25min at room
temperature and 2–4ml were loaded onto a 6% acrylamide
gel (6% 37.5:1 acrylamide:bisacrylamide, 0.5 TB). Gels
were run for 35min at 170V at 4 C. The Kd values were
calculated based on a minimum of three gel mobility shift
assays for each RNA, with the exception of F06 UCCA
and (CUGCUU)6 RNAs, which were calculated based on
two gel mobility shift assays.
Single nucleotide composition of selected RNAs
In order to examine biases in the single nucleotide com-
position that resulted during selection, we compared the
total count for each nucleotide within the randomized
region for Round 5 versus those observed in Round 0.
To evaluate the statistical signiﬁcance of the diﬀerences
observed, we calculated a conﬁdence interval (a=0.05)
for the binomial distribution using the previously
described method (27) for a population that is the
size of the sequences recovered (82 oligos 32nt
length=2624). The expected probabilities used in this
estimate were those derived from the frequencies
observed within the randomized regions of the Round 0
sequences.
K-mer enrichment
All K-mers from 4 to 6nt were counted in the ﬁnal 82
SELEX sequences, including the random sequence plus
5nt of the constant ﬂanking sequence. The inclusion of
the ﬂank allows one to analyze K-mers that overlap with
the edges of the constant sequence. To calculate a Z-score
for the observed versus expected occurrences we used
Monte–Carlo simulation to estimate the mean ( ) and
standard deviation (s) for the occurrence of all K-mers
in 1000 independent populations of 82 sequences con-
structed using the same random biases used to synthesize
the oligos used as input in the SELEX experiment. The
Z-score (Z) for each K-mer was calculated according to
Equation 1 where m is the mean observed over the random
samples, s is the standard deviation for the K-mer occur-
rence within the random samples and x is the observed
occurrence within the population derived from SELEX.
Z ¼
x    
 
ð1Þ
Construction of splicing reporter constructs
The construction of the MBNL–eGFP plasmid was
previously described and obtained from the laboratory
of Maury Swanson (28). The DMPK-CUG960 plasmid
was obtained from the laboratory of Thomas Cooper
(24). The wild-type PLEKHH2 minigene (PLEKHH2
WT) was constructed by amplifying regions of the
PLEKHH2 gene from HeLa genomic DNA using PCR
primers containing unique restriction sites. Introns
20 and 21 are 2.4 and 1.7Kb, respectively, so both were
truncated using primers directed against the introns. The
construct was built in three segments. The front segment
contains exon 20 and the ﬁrst 922nt of intron 20 ﬂanked
by KpnI and BamHI sites (sense primer: 5’-CGGGGTAC
CAAATGCTGCAGTTGACTCTCC-30 and anti-sense
primer: 50-CGCGGATCCCTGTGGCTAACAGGCAG
TCA-30). The middle segment is ﬂanked by BamHI and
NotI sites and contains the last 194nt of intron 20, exon
21 and the ﬁrst 297nt of intron 21(sense primer: 50-CGCG
GATCCGGATCATAGATCTGACCCAATG and
anti-sense primer: 50-AGGAACATAGCGGCCGCTTG
AATGAACACCCACTAATGC). The ﬁnal segment is
ﬂanked by NotI and XhoI sites and contains the last
958nt of intron 21 and exon 22 (sense primer: 50-AGGA
ACATAGCGGCCGCATCTGCCTACAGGGCACTT
G-3 and anti-sense primer: 50-CCGCTCGAGCCATTCA
TGAAGTGCACAGG-3). The ligated segments were
inserted between KpnI and XhoI sites of the pcDNA3
plasmid (Invitrogen), which contains the hCMV
promoter/enhancer and a bovine growth hormone
(BGH) poly(A) signal after the multiple cloning site.
The PLEKHH2-SM1F, PLEKHH2-SM1R,
PLEKHH2-SM2, PLEKHH2-SM3 and PLEKHH2-SM4
constructs were all created from the PLEKHH2 WT
template. To create PLEKHH2-SM1F, six, tandem
copies of the SELEX motif 50-CUGCUU-30 were
inserted into intron 20 of the PLEKHH2 minigene using
PCR and standard cloning techniques. The 36-nt SELEX
motif repeat, ﬂanked by ClaI and PacI unique restriction
sites (a total of 50nt), was inserted 40nt upstream of the 30
splice site of intron 20, and replaced 36-nt (positions –76
to –41 relative to the 30 splice site) of the intron to ensure
that the relative size of the intron remains ﬁxed.
PLEKHH2-SM1R was created in the same manner
except the six SELEX motifs were inserted into
the intron backwards, 50-UUCGUC–30, as a negative
control. PLEKHH2-SM2, PLEKHH2-SM3 and
PLEKHH2-SM4 were also created in the same manner,
but contain six tandem copies of 50-CUGCCU-30,5 0-CCG
CUU-30, and 50-CCGCCU–30 motifs, respectively.
Construction of ATP2A1 splicing minigene
The wild-type ATP2A1 minigene was constructed by
amplifying the region of the ATP2A1 gene from HeLa
genomic DNA containing exon 21, intron 21, exon 22,
intron 22 and exon 23 using PCR primers (sense primer:
50-GGGGTACCACCTCACCCAGTGGCTCATG-30
and antisense primer: 50-CGGGATCCCACAGCT CTGC
CTGAAGATG-30) containing unique KpnI and BamHI
Nucleic Acids Research,2010, Vol.38, No. 7 2469restriction sites. The PCR product was puriﬁed, digested
and ligated into the pcDNA3 plasmid.
The ATP2A1 deletion minigene was created by deleting
151 residues of intron 22 (positions –117 to –267) using
standard PCR techniques. The deletion minigene was
created in two segments; the front portion (antisense
primer: 50-TGCTTACAATTGACGGCTCCAGGTGGA
GCTGCGAGCACAAGTG-30) contains exon 21, intron
21, exon 22, and the ﬁrst 116nt of intron 22 ﬂanked by
KpnI and Mfe1 restriction sites. The second section (sense
primer: 50-TGCTTACAATTGGGGCTGCAGTGGGG
GGGGGCGGG-30) contains the last 171nt of intron 22
and exon 23 ﬂanked by MfeI and BamHI sites. The
digested fragments were ligated in the KpnI and BamHI
sites of pcDNA3.
Cell culture and transfection
HeLa cells were routinely cultured as a monolayer in
DMEM+GLUTAMAX media (Invitrogen) supple-
mented with 10% Fetal Bovine Serum (Gibco) at 37 C
under 5% CO2. Prior to transfection, cells were plated in
six-well plates at a density of 1.8 10
6 cells/well. Cells
were transfected 18–24h later at  80% conﬂuency.
Plasmid (1mg/well) and when applicable antisense
oligonucleotide (ASO) (100pmol/well) were transfected
into each well with 5ml Lipofectamine2000 (Invitrogen)
following manufacturer’s protocol. All ASOs contained
a2 0-O-Methyl modiﬁcation at every base and
phosphorothioate backbones. The sequences of ASOs
used herein to target intron 22 of the ATP2A1 minigene
are as follows: ASO1 (50-GGGCAAGAAGGGGGTGAT
ACCTGTG-30), ASO2 (50-GGCGCGGGTGGCAGGGG
CACAGCA-30), ASO3 (50-TTGACGGCTCCAGGTGG
AGCTGCG-30), and ASO4 (50-GGCAGGCGGCAGGA
GGGCAGCGAG-30). In double transfection experi-
ments, 500ng of each plasmid was transfected into a
single well; however, in single transfection experiments
500ng of empty pcDNA3 vector was used to normalize
plasmid concentration between wells. Cells were harvested
18–24h after transfection using TriplE (GIBCO) and then
pelleted by centrifugation. RNA was isolated from the cell
pellets using an RNeasy kit (QIAGEN).
In vivo splicing: RT-PCR
Splicing assays were conducted as described earlier (29).
Brieﬂy, isolated RNA (500ng) was incubated with 1 unit
of RQI DNase (Promega) in a 10ml reaction for 1h at
37 C. DNased RNA [2ml (100ng)] was reverse transcribed
in a 10ml reaction (1:5 dilution) using Superscript II
(Invitrogen), according to manufacturer’s protocols, with
the exception that we used half the recommended amount
of Superscript II. All PLEKHH2 reporters and the
ATP2A1 minigenes were reverse transcribed using an
antisense primer (50-AGCATTTAGGTGACACTATAG
AATAGGG-30) designed to the Sp6 promoter site of the
pcDNA3 plasmid. The minus reverse transcription ( RT)
reactions were treated identically to plus reverse transcrip-
tion (+RT) reactions except the Superscript II was
replaced with water. All reverse transcription reactions
(2ml) were subjected to 22 rounds of PCR ampliﬁcation,
which was found to be within the linear range for all
primers used (data not shown), in a 20ml reaction (1:10
dilution). PCR was conducted to analyze the splice
products of all PLEKHH2 reporters using the sense
cloning primer designed to exon 20 and the antisense
cloning primer designed to exon 22 described earlier.
The ATP2A1 WT sense and antisense cloning primers
designed to exon 21 and 23, respectively, were used for
PCR of the ATP2A1 minigene. For quantiﬁcation of the
PLEKHH2 reporters, PCR was conducted using
radiolabeled sense cloning primer. For the ATP2A1
minigene splicing, radiolabeled antisense primer was
used in the PCR reaction for quantiﬁcation. The resulting
PCR products were resolved by electrophoresis on 8%
(19:1) polyacrylamide native gels. The gels were dried
and exposed overnight on a phosphorimager screen.
Quantiﬁcation of the radioactive bands corresponding to
splice products was performed using ImageQuant
software (Molecular Dynamics). The percent of exon
inclusion was calculated by dividing the amount of the
band corresponding to inclusion splice product by the
total amount of splice product (calculated by adding the
inclusion splice product band to the exclusion splice
product band). Percentage of exon exclusion was
computed in the same manner, except the exclusion
product was divided by the total amount.
Calculation of the enrichment of YGCY motifs in the
regions ﬂanking exons mis-spliced in DM1
The identities of 24 exons that are mis-spliced in human
DM1 tissues were gleaned from a search of literature
(Supplementary Table S2). The sequences for the exons
and up to 200nt of the ﬂanking introns were recovered
from public databases. If the intron was <400nt in length
only the adjacent half was evaluated. Each exon was
categorized as ‘excluded’ (E) or ‘included’ (I) if it was
generally excluded or included, respectively, in normal
tissues relative to DM1 tissues. The frequency of YGCY
motifs in the ﬂanking intronic regions was calculated
according to Equation 2 where n equals the number of
YGCY motifs observed, l equals the length of each
intronic sequence evaluated and k indicates the number
of introns evaluated. The denominator eﬀectively repre-
sents the total number of positions that could contain
the motif within the set of sequences evaluated.
f ¼
n
P
k ðl   3Þ
ð2Þ
The background frequency of YGCY in the
upstream and downstream intronic ﬂanks for all human
introns (according to the UCSC hg18 annotation)
was also calculated. The actual numbers are contained
in Supplementary Table S3. The upper and lower
conﬁdence intervals (a=0.01) for the frequencies
expected in a randomly drawn sample that is the size of
the regions of interest was calculated using the back-
ground frequencies, the sample sizes, and the method of
Agresti et al. (27).
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Doped SELEX with an MBNL1 RNA-binding site
MBNL1 binds just upstream of exon 5 in the TNNT2
pre-mRNA (7,24). It has been previously shown that a
32-nt RNA corresponding to this region binds MBNL1
with high aﬃnity and that mutations that disrupt MBNL1
binding also disrupt MBNL1-regulated exclusion of the
downstream exon (7). In order to identify the nucleotides
that contribute most to recognition by MBNL1, we per-
formed a doped SELEX experiment (30). Unlike tradi-
tional SELEX, which starts with a pool of uniformly
random RNAs, doped SELEX begins with a population
of RNAs synthesized such that they are biased toward a
speciﬁc starting sequence, but each position is still allowed
to vary. For this particular experiment we began with a
population of 32-nt RNAs synthesized such that each
position was 51% likely to be the equivalent base found
in the 32-nt TNNT2 MBNL1-binding site. Each of the
other nucleotides had a 16.3% probability of being used.
For example, the ﬁrst position in the 32-nt region was
cytidine, so in 51% of the RNAs it remained a cytidine,
while the other 49% of the time the other three nucleotides
were equally incorporated at that position (Figure 1A).
This allowed MBNL1 to sample other possible residues
at each position with a bias toward the endogenous
residue. The 32 endogenous nucleotides were ﬂanked on
each side by constant regions, 26nt on the 50 side and 23nt
on the 30 side, that are necessary for PCR and transcrip-
tion. The MBNL1 construct included residues 1–260 and
an N-terminal GST tag. This protein, termed MBNL1
throughout the article, bound RNA as tightly as the
full-length version of MBNL1 (7).
After ﬁve rounds of selection, the binding aﬃnities of
the recovered pools of RNAs were tested using a gel
mobility shift assay. The binding aﬃnity of MBNL1 was
low for pool zero (Kd of >1.2mM) and high for pool ﬁve
(Figure 1B). Pool 5 RNA-bound MBNL1 with slightly
higher aﬃnity compared to the endogenous
TNNT2-binding site template (Figure 1B, compare lanes
1–6 and lanes 13–18), which demonstrated that we were
successful in selecting RNAs with high aﬃnity toward
MBNL1. Eighty-two sequences were obtained from
Round 5, and there were no duplicates, indicating that
over-selection did not take place. The sequence most
closely related to the endogenous TNNT2 template con-
tained six bases that diﬀered from the original TNNT2
site. This result was not surprising, as pool 0 started out
with only a 1 in 2 10
9 chance that a sequence would be
identical to the endogenous template. Pool zero was
sequenced (96 individual sequences) to insure that there
was no bias in the initial pool, other than the designed
doping. Analysis of these sequences demonstrated that
pool 0 sequences had compositions similar to that
expected according to the doping design. However,
the pool 0 RNAs did show a slight enrichment in the
number of uridines and a corresponding slight decrease
in the number of cytidines expected according to the
doping design (Figure 2A).
The majority of SELEX-derived RNAs bind MBNL1 with
high aﬃnity and are highly enriched in YGCY motifs
MBNL1’s endogenous TNNT2-binding site is pyrimidine
rich (28% U, 50% C) and purine poor (19% G, 3% A). In
order to determine if there was an overall selection for
pyrimidines over purines during the SELEX process, we
analyzed the single nucleotide frequencies for the
randomized region from the population of sequences
recovered during Round 5 and compared these to the
sequences from Round 0 (Figure 2A). This analysis
demonstrated that there was a statistically signiﬁcant
enrichment in the overall uridine and cytidine content in
the Round 5 RNAs when compared to Round 0 RNAs,
suggesting that MBNL1 has a preference for pyrimidines
over purines.
An analysis of the K-mer (4–6nt) composition of the
Round 5 RNAs relative to the composition expected by
chance (based upon the starting template and doping
regime, see ‘Materials and Methods’ section) revealed
that the Round 5 RNAs are enriched in speciﬁc K-mers
(Figure 2B and Supplemental Table S1). Meanwhile, the
same analysis identiﬁed no signiﬁcantly enriched K-mers
within the Round 0 RNA sequences (data not shown). All
of the most highly enriched K-mers contain a GC-dimer.
Of these, the most signiﬁcantly enriched contain UGCU
(107 occurrences compared to 12 expected by chance,
Z=27). Closer inspection revealed that CGCU (Z=12)
and UGCC (Z=3) are also enriched, but at lower levels
(Figure 2B and Supplementary Table S1).
We aligned all GC-dimer instances in the Round 5
sequences, plus three nucleotides on either ﬂank, and
compared these to GC-dimers found in Round 0
(Figure 2C). This analysis revealed a selection toward
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Figure 1. Round 5 SELEX RNAs bind signiﬁcantly tighter than
Round 0 RNAs. (A) The TNNT2 template used to create the pool 0
RNA for SELEX. The dark lines indicate the constant regions, while
the central 32 bases denote the doped, variable region. The arrow indi-
cates an example of the doping. For that particular position, the C was
maintained in 51% of the sequences, while G, U and A were incorpo-
rated equally in 49% of the other sequences. The structure of the
TNNT2 32mer was previously determined (7). (B) Gel mobility shift
assays of MBNL1 with the 81 nucleotide wild-type TNNT2 template
(top), Round 0 RNAs (middle), and Round 5 RNAs (bottom).
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the central GC-dimer. This, and the previous analysis,
suggests that MBNL1 has a higher aﬃnity toward
UGCU; however, since cytidines are also tolerated we
chose to represent the general MBNL1 binding site as
YGCY.
The majority of SELEX sequences contain two to six
YGCY motifs (Class I, Figure 3). Over half of the
sequences contain YGCY in the same locations as the
wild type TNNT2 CGCU motifs. However, many of
the sequences show that MBNL1 selected YGCY motifs
that are shifted with respect to the positions of the YGCY
motifs in the wild-type TNNT2. In some cases, this change
is a slight shift of the YGCY position in comparison to the
location of the wild-type motifs, whereas in other
sequences a whole new second, third or forth additional
motif appeared nearby or in a diﬀerent region.
Binding studies were performed on 12 of the SELEX
sequences to determine the aﬃnities of these sequences to
MBNL1. Almost all of the sequences tested have binding
aﬃnities roughly equal to or higher than the endogenous
TNNT2-binding site (Table 1). The SELEX sequences
were grouped into two classes. Class I contains sequences
with two or more YGCY motifs and Kds between 1 and
25nM (of the RNAs tested). Class II sequences contain
zero or one YGCY motif and have Kds>1.2mM (of the
RNAs tested). Interestingly, two sequences in Class II that
contain only one motif (C12 and B08), don’t bind
MBNL1, suggesting an important role for multiple
YGCY motifs for MBNL1 binding (Figure 3, Table 1).
To determine if the constant (non-randomized) regions
were playing a role in the binding of MBNL1 to the
SELEX sequences, the constant regions were removed
from several SELEX sequences and binding studies were
performed (Supplementary Figure S1). The addition of the
constant regions to the TNNT2 sequence only slightly
weakened binding (Kd of 30nM), compared to a Kd of
20nM for the 32mer endogenous TNNT2 site. Similar
studies were performed on three of the SELEX sequences
(F06, B07, A04) to determine the eﬀects of removing the
constant regions for these RNAs. The F06 32mer showed
similar binding to the equivalent 81mer (Supplementary
Figure S1 and Table 1). The B07 32mer bound MBNL1
with high aﬃnity (Kd of 0.66nM), which was  10-fold
tighter than the B07 81mer. The A04 32mer bound
much weaker to MBNL1 with a Kd of 180nM compared
to 6.0nM for the 81mer RNA. Although these studies
show that the constant regions can inﬂuence MBNL1
binding, in general the randomized regions appear to
contain the necessary elements for MBNL1 high-aﬃnity
binding.
Mutations in YGCY motifs in SELEX sequences decrease
MBNL1’s binding aﬃnity
To determine the importance of the YGCY motif for
MBNL1 recognition, this motif was mutated in three dif-
ferent 81mer SELEX sequences (F06, H01 and D12). The
F06 sequence contains three YGCY motifs (Figure 4A).
Motif #1 in F06 was mutated from CGCU to UCCA,
which caused a 140-fold decrease in binding aﬃnity to
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Figure 2. Nucleotide composition, K-mer analysis and the frequency of
nucleotides ﬂanking GC dimers conﬁrm a high occurrence of
pyrimidines and YGCY motifs within SELEX sequences. (A) Single
nucleotide counts for the randomized regions derived from Round 5
RNAs are compared to those expected (labeled ‘Expect’) given the
frequencies observed in the starting pool (derived from the counts
observed in Round 0). Upper and lower conﬁdence intervals
(a=0.05) are indicated above and below each of the expected values
(see ‘Materials and Methods’ section for the calculation). Also shown
are the values expected according to the original doping design (labeled
‘Design’). (B) The K-mer analysis reveals highly enriched 4-, 5- and
6-mers (p<0.01) found within the SELEX sequences from Round 5.
The 15K-mers listed have the highest Z-scores out of each K-mer size
category (4–6). Observed is the total number of occurrences of the
K-mer within the sample of 82 SELEX sequences. The expected is
the mean number of the K-mer within 1000 sets of 82 random
sequences, taking the doping into account. (C) The nucleotide
frequencies ﬂanking all GC dimers found within the SELEX Round
5 randomized regions were determined. The frequencies are represented
as sequence-logos with the size of the nucleotide corresponding to fre-
quency (numbers to the right of each nucleotide in percentages). The
nucleotides are ordered top to bottom, highest frequency to lowest
frequency.
2472 Nucleic Acids Research, 2010,Vol.38, No. 7MBNL1. The H01 sequence contains three YGCY motifs,
which were mutated from GC to CA individually (H01
CA1, HO1 CA2 and HO1 CA3), in pairs (H01 CA1-2,
HO1 CA1-3, HO1 CA2-3) or all three at once (H01
CA1-2-3) (Figure 4B, Table 1). The H01 mutants with
one or two motifs mutated bound with similar aﬃnity to
H01 (Kds of 2–10nM), with the exception of H01 CA1-2,
which bound with 12-fold lower aﬃnity to MBNL1
compared to H01. When all three motifs were mutated
(H01 CA1-2-3), binding was greatly weakened, with a
Kd>1.2mM (Figure 4B, lanes 19–24). Together, these
results demonstrate that, for this particular RNA, only
one motif is required for MBNL1 binding. However, in
the case of two SELEX sequences from Class II, C12 and
B08, MBNL1 was unable to bind them although each
contains one YGCY motif (Figure 3 and Table 1). This
indicates that MBNL1 binding is context dependent and
in some cases, requires more than one YGCY motif.
The D12 RNA contains four YGCY motifs
(Figure 4C). These were mutated from GC dimers to
CA dimers one at a time, two at a time, three at a time
or all four at once (Figure 4C, Table 1). All single, double
or triple mutant combinations of D12 RNAs have an
aﬃnity within a 10-fold range of the native sequence (Kd
of 25nM). In contrast, when all four motifs were mutated
(D12 CA1-2-3-4, Table 1) binding was drastically reduced
(Kd>1.2mM). Certain motifs within these RNAs may
play a more signiﬁcant role in MBNL1 binding, such as
the H01 motifs #1 and #2 compared to HO1 motif #3, but
in general, MBNL1 does not appear to have a preference
for speciﬁc YGCY motifs in these RNAs (Table 1). In
conclusion, mutations in these SELEX sequences
indicate that MBNL1 requires at least one YGCY for
high-aﬃnity binding.
YGCY motifs are suﬃcient for MBNL1 to regulate
splicing in a PLEKHH2 minigene reporter
In order to determine if YGCY is suﬃcient for MBNL1 to
regulate splicing, we created an artiﬁcial binding site using
the SELEX CUGCUU K-mer (SELEX motif 1, SM1)
because it had the highest Z-score in the K-mer analysis
of 6-mers enriched in the SELEX sequences (Figure 2B).
In addition, CUGCUU is found in several SELEX
sequences that MBNL1 binds with high aﬃnity (E01,
A04, H01). MBNL1 binds (CUGCUU)6 RNA with high
aﬃnity in a gel mobility shift assay (Figure 5A).
Class II Class I cont. Class I
WT  CCUGUCUCGCUUUUCCCCUCCGCUGCGGCCAC
E10.CCUGCUUCGCCUUUCCAAACCGCAGCUUUGUC
B04.CCUGCUUCGCCUUCUUGUUACGGAUCGGGUAC
B02.CCAUGCUUGCGUUUCCCUUCGAAGUCGUGCAC
F12.CCAUGCUCUUCGCCUGCCUACCUUCAAUGCAC
E11.CCUCUGCUUGCAAUCCCGUCCGUUGCCGAUAC
D05.CCAUUGCUGCUUGUAGUUUCUUCACCGACCUA
B09.CCUCUGCUGCUUUUUGCCUACUAUGAGUUUGC
B10.CCUUUGCUGCUUUCUUCGUCCCUGUCGCCAU
C06.CCAUAACCGCUUCUGCCCUAGUCACCGUGUUC
G04.CCUGGCUUGCUUUUAUCGGUCGUGAAUGCAUC
D09.CCCGCCUCAUUGCUACAUUCGUUCGCGGCUGC
D04.CCUGCCGCGCCUUUCGCUUUGACGGUUCCCGU
B01.ACCGUCUGGCCAUGCCCAUACGCUUUUAUCAC
A12.GCCCUUUCGAGUAUCGAUACUGCUGCGACGUC
A07.CCAGCGUUGGUCGUCCCGUACACGCUUGCGCC
H04.CCAGCUUGCCCUUGCACAUUCGCCGCUGCACG
C12.CCUUGGUUGUCAGUCCGUUCAAUUGCUGUCCC
B08.CCUACAUCGGUUGUUUGGUCCUCUAGUGCUAG
E09.CUUAACGGACUUUGCACCUCUGGUGGUUAUAC
WT  CCUGUCUCGCUUUUCCCCUCCGCUGCGGCCAC
E03.CCGCUCUGCUUUGCUCCUGUUGCUACGCGUUC
E12.CCGCUGCUGCUUAUUGCCUAACGACCGUGUUG
C11.CCUGCUCUGCUUUUGCCUUGCGUUCGGGUUAG
A10.CCUGCUUUGCUAAUACCAGCUGCUGUCGUUAC
G06.CCUGCUUGCUUUUCCGCCUACCCUGCUGUCAC
G08.CCUGCUUUGCUAUGCUCCUAGUCUGUGCUCAC
H07.CCUGCUUCGCUGUUGCCUUUCGGUUCUCCAAC
H01.CCUGCUUUGCUAUUGCGCUGCAAUUCCUGUUC
C04.CCUGCUUCGCUGUAACCUCUCGUUGCCGUGUC
G12.CCUGCUUUGCUUUGCGACCACGCUCCCGUACA
F01.CUUGCUUUGCUUUACUCCGCUGCUGCUGUCAC
H10.CCUGCUUUGCUUUUCCUCGUCUCUCGGUGCAC
B05.CCUGCUUUGCUUUCCCAUUCGUUUGCGGACAC
A04.CCUGCUUCGCUUCUGCAUUGUUCGGCCGGUUG
D11.CCUGCUUCGCUUUACUCUUCCGCUGCGUAAUC
F03.CCUGCUUCGCUUAUCGCCUGCUAUGCCGCUAC
G01.CCUGCUUCGCUUCUCCAUCACGUACCAGACUC
G02.CCUGCUUCGCUUUUGCCAUGUUCAGCGUAGUC
G10.CCUGCUUCGCUUAUCCUCUCAGCUACUGCCAC
A08.CCUGCUUCGCUAUUCCGCUUUGUAGCCAUCGU
C05.CCUGCUUGUUAUGCUUGAUUGCCUGUUUCGAG
E07.CAUGCUUCCCAUUUCUGCUUUGCUACGCACGU
C10.CCUGCUUAGCUUUUCGCUUAAACUGGCCACAC
H11.GACCGCUCGCUUUUUCCUAUUCCUGCUUGUCG
H05.CCGUGCUCGCUGAUCACGACAGCUUGGACCUC
D10.CCUUGCUCGCUCUUUCGCUAUGCUUCGGUCAC
H06.CUAUGCUUGCUACUACCGUCCUACUCGUGCAC
A02.CCGUGCUUGCUUAUACCGUUACAUGUCGCCAG
A06.CCUUGCUUGCUUAAUGGUUCAGCGAUCGGUAG
G09.CCUUGCUUGCUUGUUUCCACGUCUCGAGAUGG
E04.CUUCGCUCGCUUUGCAACUCCACGAUCGCGAU
E05.CUUCGCUUGCUUUUCCACACCGCGGUCUUCAC
WT  CCUGUCUCGCUUUUCCCCUCCGCUGCGGCCAC
A11.CCACGCUUGCUUUUUCGCUACCGCACAAUCAG
D01.CCUUGCUUGCAUUGCGCUUAUGCUUGGCCUUC
D08.CUACGCUUGCUUUUCGCUUGCCCUGCUGCUUC
G11.CCUGUGCUGCUUUUUGUCCACGCUACUGCUAU
C07.GAUGCGCUGCUUUGCUUUUCAGGUUCGGCCAC
F07.CCACUGCUUCAUUGAGUCUCUGCUGCGCUCUA
D07.CCUGCGCUUAGUUCCGAUGUUCCGCUGCUAC
F09.CCAGUUGCUUGUUUGACGUCGGGUACCGCUAC
A05.CCUCUCGCUUUGCUCCCCCACGGUUCGGUCAU
B06.CCAGUCGCUUUUGUUCCAUCUGCUGUAGUCAC
C02.CCAAACGCUUCCUCCUGCCUCAUUGCCAUGCU
E01.CCCAUCGCUUAAUUCACUCCCUCUGCUUGCAU
H03.CCUUUACGCUUCUUUCGCUUUGUGUGGGCUAG
B12.CCGACCUCGCUUUUCACCUCCGCUCCAUCGCC
C01.AUUGCCACGCUUUGCCUCUACGCUACAAUCUU
H12.CUUGCCUCGCUUUUAUGACGCUGUGUUCCGAU
C09.CCUGUUUCGCUUUUCACCGUCACUGCUGCCCU
D03.CCUUUCUCGCUUUGCCUUUACGCUGCGUCCAC
F02.CUAGCUUCGCUUUUCUUAGUCACUUCGGGCGC
F06.CCGAUCCCGCUUAUGCCAUCCGCUGCAGUCAC
F11.CCCGGCUCGCUUUUGCUACUCCCUGCUGUCAC
A09.CGUCCCUUGCUUUUCCCUUCCGCUGCCGUCGC
A01.CCUGCCUUGCUUUUCCACUGCUUUGCUCUCAC
F04.CUGAUGCCGCUUUACGCUUCCGCUACGUACAC
B07.UGUUCCUCGCUUUUCGCCUCCGCUUCCGCCGC
F05.CCUCUUUCGCUUUUUCCGCUUGCUGCAGCUAC
F10.CUUCUCUCGCUUUUCGCCUUCGCUGCCGCUUC
D12.CCUCCUGCGCUCUUUGCUUGCCCUGCUGUGUC
C03.CAUGUCCCUGCUUCCCUUUCCGCUGCUUGCUU
H09.CCCCAUCUCGCUUUGCUACUCCGCCUCUACGAC
E06.CCCAUGCCGCAAUACCGCUCCGCUAACGCUUC
Figure 3. SELEX sequences are highly enriched in YGCY motifs. The YGCY motifs highlighted in all 82 Round 5 SELEX sequences. Class I RNAs
contain two or more YGCY motifs and bind MBNL1 with high aﬃnity, while Class II contain zero or one motif and do not bind MBNL1 with high
aﬃnity. The wild-type TNNT2 sequence contains two YGCY motifs and is shown at the top of each column for reference.
Nucleic Acids Research,2010, Vol.38, No. 7 2473We designed several splicing reporter minigenes based
on the PLEKHH2 gene transcript. This transcript was
chosen because MBNL1 does not normally regulate the
splicing of this minigene. We designed several minigenes
that include exons 20–22 and the intervening introns
(Figure 5B). We replaced 36nt (positions –76 to –40)
with a 50-nt sequence containing six repeats of either C
UGCUU (PLEKHH2-SM1F) or, as a negative control, U
UCGUC (PLEKHH2-SM1R), the reverse of SM1. We
also wanted to explore the eﬀect of C versus U in the
positions immediately ﬂanking the GC core of the motif.
To this end, we created three additional splicing reporter
constructs in the same manner as PLEKHH2-SM1F using
variations of SELEX motif 1; PLEKHH2-SM2,
PLEKHH2-SM3 and PLEKHH2-SM4. PLEKHH2-SM2
contains six repeats of CUGCCU (the changed nucleotide
is underlined). This reporter was designed to assess the
eﬀects of a C, instead of a U, immediately 30 of the GC.
Similarly, PLEKHH2-SM3 contains (CCGCUU)6,t o
evaluate the eﬀects of a C at the position immediately 50
of the GC. PLEKHH2-SM4 contains a C at both posi-
tions ﬂanking the GC core to give (CCGCCU)6 (Figure
5B). In all cases the motifs are positioned  10nt upstream
of the putative branch site and of the poly-pyrimidine
tract. It is important to note that the reversed sequence
(PLEKHH2-SM1R) contains the same overall pyrimidine
content and the same number of guanosines as in SELEX
motif 1; however, in the reversed sequence the UGCU
motif is converted to UCGU. All three constructs were
transfected into HeLa cells with or without an MBNL1
protein expression vector (Figure 5C). Splice products
were observed via harvesting of HeLa RNA and subse-
quent RT-PCR using primers to PLEKHH2.
Several splicing products were observed for the
PLEKHH2 WT construct (Figure 5C, lane 1). The
major splice product (Figure 5C, lane 1, middle band)
corresponds to inclusion of exon 21. We also observed a
smaller amount of product that arose from usage of an
alternative 50 splice site lying downstream of the normal 5’
splice site (Figure 5C, lane 1, top band). Very little
product (5%) corresponding to the skipping of exon 21
(Figure 5C, lane 1, bottom band) was observed in the WT
construct. The splicing pattern for PLEKHH2 WT was
completely unaﬀected by expression of MBNL1
(Figure 5C, lane 3 versus lane 1 and 5D), which demon-
strates that the WT splicing pattern is MBNL1
independent.
The overall splicing pattern observed for
PLEKHH2-SM1F, without expression of MBNL1, was
very similar to that observed for the PLEKHH2 WT con-
struct (Figure 5C, lane 5); however, exon 21 exclusion is
increased to 15% for this reporter (Figure 5D). In sharp
contrast to the eﬀect seen for PLEKHH2 WT, when
MBNL1 was co-expressed with the PLEKHH2-SM1
reporter, 75% of the splicing product observed corre-
sponded to the skipped isoform (Figure 5C, lane 7 and
5D) demonstrating that MBNL1 robustly suppresses
inclusion of exon 21 in this synthetic construct. HeLa
cells contain a low level of endogenous MBNL1; this
could explain the low level of the exon 21 skipped
isoform seen when expressing PLEKHH2-SM1without
co-expression of MBNL1 (Figure 5C, lane 5 versus lane
1).
The splicing pattern for PLEKHH2-SM1R (containing
SELEX motif 1 reversed), like the other constructs,
consists primarily of the exon 21 inclusion isoform
(Figure 5C, lane 9), with only 2% exon 21 exclusion.
However, in addition to the small amount of transcript
derived from usage of the downstream alternative 50
splice site, there is a minimal amount of higher molecular
weight product corresponding to a cryptic 30 splice site.
Importantly, and in sharp contrast to PLEKHH2-SM1F,
when MBNL1 is co-expressed with PLEKHH2-SM1R
there is no corresponding increase in skipping of exon
21 observed and the overall percentage of exon 21 exclu-
sion remains unchanged at 2% (Figure 5C, lane 11 versus
lane 9 and 5D).
The splicing patterns for PLEKHH2-SM2 and
PLEKHH2-SM3 were very similar to PLEKHH2-SM1F,
with exon 21 exclusion of 28 and 26%, respectively
(Figure 5C lanes 13 and 17 and 5D). Also, similar
splicing changes were observed in both reporters
with MBNL1 co-expression leading to strong MBNL1-
induced increases in exon 21 exclusion to 70 and 73%,
respectively (Figure 5C, lanes 15 and 19 and 5D). These
ﬁndings suggest that MBNL1 recognizes a C upstream or
Table 1. Binding aﬃnities of MBNL1 for selected SELEX sequences
Sequence Kd (nM) 81mer Kd (nM) 32mer
WT cTNT 30±20. 20±10
D01 25±6
E01 5±2
H05 25±15
C12
a >1.2mM
B08 >1.2mM
H06 4±4
E12 13±9
B07 15±8 0.7±0.5
A04 6±5 180±130
F06 1.0±0.1 9±7
F06 UCCA  140
H01 10±5
H01 CA1
b 10±3
H01 CA2
b 2.3±0.6
H01 CA3
b 3.9±1.2
H01 CA1-2
b 120±35
H01 CA1-3
b 21±9
H01 CA2-3
b 8.3±2.4
H01 CA1-2-3
b >1.2mM
D12 25±7
D12 CA1
b 11±6
D12 CA2
b 24±12
D12 CA3
b 4.9±1.2
D12 CA4
b 8.4±2.8
D12 CA1-2
b 20±11
D12 CA1-4
b 3.9±1.8
D12 CA 2-4
b 3.8±0.7
D12 CA1-2-4
b 20±3
D12 CA1-2-3-4
b >1.2mM
aGray shading refers to SELEX RNA oligomers in Class II, no shading
refers to Class I.
bCA refers to GC to CA mutations in the 5’-YGCY-3’ of the SELEX
RNA.
2474 Nucleic Acids Research, 2010,Vol.38, No. 7downstream of the GC core equally eﬃciently when the
other Y position in the YGCY motif is a U.
Splicing of the PLEKHH2-SM4 construct gave 2%
exon 21 exclusion (Figure 5C lane 21). Surprisingly,
however, only a slight increase in exon 21 exclusion to
10% was observed upon co-expression of MBNL1
(Figure 5C, lane 23 and 5D). This observation suggests
that MBNL1 recognizes CGCC less eﬃciently than
UGCU, UGCC or CGCU, which suggests that MBNL1
requires at least one U ﬂanking the GC core for
high-aﬃnity recognition.
Together, these results demonstrate that, at least in the
case of PLEKHH2, insertion of multiple YGCY motifs is
suﬃcient for conferring MBNL1-dependent alternative
CCUGCUUUGCUAUUGCGCUGCAAUUCCUGUUC
CCUCA CAUUUCA CAUAUUGCCA CAUGCAAUUCCUGUUC
CCUCCUGCGCUCUUUGCUUGCCCUGCUGUGUC
H01
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C
Figure 4. Mutations in YGCY motifs decrease binding to SELEX RNAs. (A) SELEX RNA F06 has three YGCY motifs, indicated by motif #1, #2
and #3. Pictured are gel mobility shift assays to F06 and mutated F06 (F06 UCCA) to MBNL1, with the Kds listed below. The residues in bold
indicate mutated residues. Notice the concentrations of MBNL1 used in the F06 gels are diﬀerent than the concentrations used in 4B and 4C. (B)
RNA H01 contains three YGCY motifs and binds MBNL1 with a Kd of 14nM, indicated by the gel mobility shift assay labeled H01. Mutations
were made within each motif individually and in combination. Representative gel mobility shift assays and Kds of MBNL1 binding to one of each
type of mutation are shown. Mutations relative to H01 are shown in bold. H01 CA1 indicates the GC in motif #1 was mutated to CA, H01 CA1-3
indicates motifs #1 and #3 were mutated (but not motif #2). H01 CA1-2-3 has all three motifs mutated. All RNAs are 81-nt long. (C) D12 contains
four YGCY motifs and binds MBNL1 with a Kd of 25nM, indicated by the gel mobility shift assay labeled D12. D12 CA1, D12 CA1-2 and D12
CA1-2-3-4 refer to mutations in the corresponding motifs shown in the lower portion of the ﬁgure. Representative gel mobility shift assays and Kds,
one from each class of mutation, are shown for D12 mutant RNAs bound to MBNL1.
Nucleic Acids Research,2010, Vol.38, No. 7 2475splicing upon an exon that is normally constitutively
included and does not normally require MBNL1 for
splicing regulation. The observation that the reversed
sequence is incapable of conferring MBNL1-dependent
splicing demonstrates that a GC step (rather than a CG
or GU step) is necessary for MBNL1-speciﬁc regulation.
This distinction diﬀerentiates the MBNL1-binding site
from the compositionally similar ETR-3-binding site:
UGUU (31). Additionally, the observation that the exon
21 exclusion ratio in PLEKHH2-SM1F, PLEKHH2-SM2
and PLEKHH2-SM3 reporters are all robustly increased
with MBNL1 co-expression suggests that MBNL1 recog-
nizes a C or U ﬂanking the GC core of the motif (i.e.
CGCU or UGCC) with similar eﬃciency. Importantly
however, MBNL1 co-expression with the PLEKHH2-
SM4 reporter was much less eﬃcient at inducing exon
21 exclusion in the reporter. This observation suggests
that MBNL1 tolerates a C at either Y position only as
long as the other position remains a U, therefore MBNL1
does not appear to recognize CGCC as well as it recog-
nizes UGCU, UGCC or CGCU.
Novel putative MBNL1-binding sites identiﬁed in
pre-mRNAs mis-spliced in DM1
We predicted potential endogenous MBNL1-binding sites
by identifying YGCY motifs clustered within introns
ﬂanking ﬁve exons mis-spliced in DM1. We evaluated
these sites in vitro to determine if MBNL1 can bind
these potential sites with similar aﬃnity to that of the
known TNNT2 site. Two sites in the MBNL1
pre-mRNA upstream of exon 7, one site downstream of
ATP2A1 exon 22, one site in the MBNL2 pre-mRNA
upstream of exon 7, one site downstream of exon 11 in
INSR and one site upstream of exon 5 in GRIN1 were
tested for MBNL1 binding (Figure 6). MBNL1 site #1
contains upstream residues 35–79 (45mer) and has three
YGCY motifs. MBNL1 site #2 contains upstream residues
154–193 (40mer) and has one YGCY motif. The potential
MBNL1-binding site found in ATP2A1 pre-mRNA has
ﬁve motifs and is located downstream and contains
residues 117–156 (40mer). The site in the MBNL2
pre-mRNA is between upstream residues 50–89 (40mer)
and contains three motifs. The Kds of MBNL1 to the
potential RNA-binding sites; MBNL1 site #1, MBNL1
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Figure 5. Multiple YGCY motifs embedded in pyrimidines are suﬃ-
cient for MBNL1 regulated splicing of a PLEKHH2 reporter minigene.
(A) Gel mobility shift assay of MBNL1 to SELEX motif 1(CUGCUU)6
RNA. (B) A diagram of the PLEKHH2 minigene reporter,
PLEKHH2-SM1F, containing six copies of the SELEX motif 1
(CUGCUU). Additional reporters, PLEKHH2-SM1R,
PLEKHH2-SM2, PLEKHH2- SM3 and PLEKHH2-SM4 were
constructed similarly and only vary from PLEKHH2-SM1F in the
sequence of the inserted motif, (UUCGUC), (CUGCCU),
(CCGCUU) or (CCGCCU), respectively. Nucleotide variations in the
motif around the GC core (bold) are underlined. The gray exon 21
refers to the MBNL1 regulated exon. (C) HeLa cells were transfected
with either wild-type PLEKHH2 splicing reporter plasmid (PLEKHH2
WT), PLEKHH2-SM1F, PLEKHH2-SM1R, PLEKHH2-SM2,
PLEKHH2-SM3 or PLEKHH2-SM4 with or without MBNL1 over-
expression (+MBNL1). The RNA was harvested and RT-PCR per-
formed to determine the splice products. Representative agarose gels
are shown. A diagram of splice products including exon 20 or 22 (white
boxes), exon 21 (gray boxes), the alternative 50 splice site (downstream
of exon 21) (black boxes) are shown to the left of their corresponding
bands in the gel. (D) Quantiﬁcation of the splicing of the PLEKHH2
reporters with (open circles) and without MBNL1 (solid circles)
co-expression using radiolabeled RT-PCR.
2476 Nucleic Acids Research, 2010,Vol.38, No. 7site #2, ATP2A1 and MBNL2 sites were measured as 11,
45, 15 and 5.8nM, respectively (Figure 6B), well within
the range of MBNL1’s RNA-binding aﬃnity to TNNT2
(Kd of 20nM). MBNL1 bound the 40nt GRIN1 and
INSR RNAs, each containing two YGCY motifs, but
did so with lower aﬃnity (Kds of 280 and 120nM, respec-
tively). This observation suggests that aspects other than
the YGCY motifs, such as pyrimidine content of adjacent
regions of RNA, number of motifs, and RNA structure
may also play a role in MBNL1’s RNA-binding aﬃnity.
Although these other aspects almost certainly play a
role in MBNL1 binding, simply searching for YGCY
occurrences has proven a fruitful method for predicting
potential MBNL1-binding sites.
Multiple YGCY motifs contribute to MBNL1-regulated
splicing of the ATP2A1 exon
In order to validate the functionality of YGCY as the
MBNL1 recognition motif in an endogenous target we
created a splicing reporter minigene of the ATP2A1 tran-
script. Our minigene contains exons 21, 22 and 23 of the
ATP2A1 transcript and the intervening introns
(Figure 7A). In DM1 patients, this exon is aberrantly
excluded and thus is potentially regulated by MBNL1,
as shown in mouse Atp2a1 (32,33). As expected, our
ATP2A1 reporter gave two major splicing product
bands, corresponding to exon 22 inclusion (Figure 7B,
lane 1, top band) and exon 22 exclusion (Figure 7B, lane
1, bottom band). For the ATP2A1 minigene we observed
B
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5’ CCUUUAUUGUGCAUGCU UGCUUAGUCUUGUUAUUCGUUGUAUAU 3’
5’ UGCC UGCCACUGCUGCUGCU UGCUGCUGCUGCGCU CGCUUCCAGUCAGGGUGGGCCGC 3’ 
5’ GCACCUCUGCUUGCU UGCUUGCUGUUUACCUGUAUGUUAAUUCGCU CGCUUG 3’ 
5’ GCCGAGGAGGUGGUGUGAUUGCU UGCUUUAGCGCC CGCCGUCAUUUUC 3’
5’ GCGGCGGGCAGCUGUGCU UGCUGGAGAGCAGAUGCU UGCUUCACCAAU 3’
11  nM
45  nM
15  nM
5.8  nM
280  nM
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mouse Tnnt3 5’    CAUGUGCGCU CGCUUGUGCC UGCCCACACC      3’
TNNT2
MBNL1 SITE #1
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ATP2A1
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Yuan 2007
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chicken TNNT2 5’ CGCU CGCUUUCCUUUCAUUCUUUCACUUCUCUGCUGCU UGCUGCUUUU 3’
mouse Atp2a1 5’ CCACUGCUGCU UGCUGCUGUUGCC UGCCACUGCCCGCU CGCUUCCACAUGA 3’
5’    UGCCUGCC UGCCUGCCUGCC UGCCUGCCUGCC UGCCUGC      3’ CCUG REPEATS
Figure 6. YGCY motifs are found in multiple MBNL1 binding sites. (A) Shown are 12 RNAs that MBNL1 binds. The Kds on the right are reported
in the literature (reference) or in the current study. Three studies used crosslinking (‘x-link’) to determine that MBNL1 binds speciﬁc RNAs, but did
not identify aﬃnities (12,24,33). Kino et al. used a yeast three-hybrid (‘yeast 3-hyb.’) assay to determine relative aﬃnities of MBNL1 for CUG
repeats, however no Kds were determined (15). YGCY motifs are highlighted in black. The lengths of the RNAs used for binding studies were 40nt
for MBNL1 site #2, ATP2A1, MBNL2, GRIN1, INSR, 45nt for MBNL1 site #1, and 32nt for human TNNT2. The two CUG repeat Kds reported
were calculated under diﬀerent binding conditions. The Kd reported for human TNNT2 was from this study (measured via gel mobility shift assays).
The percent pyrimidine was calculated based on the sequences that the various binding studies were performed with. The percent pyrimidine
calculations in parenthesis were calculated based on the sequences shown in the ﬁgure (binding studies were performed on larger regions of
RNA in some cases). (B) Representative gel mobility shift assays and Kds to MBNL1 are shown for all binding sites identiﬁed in this study. The
concentration (nM) of MBNL1 is indicated above each gel.
Nucleic Acids Research,2010, Vol.38, No. 7 247722% exon 22 inclusion when spliced in HeLa cells
(Figure 7B, lane 1 and 7D). As previously mentioned
HeLa cells express some endogenous MBNL1, so the
exon inclusion observed for the reporter is most likely
due to exon inclusion induced by the endogenous
MBNL1. In DM1, it is thought that MBNL1 is seques-
tered away from the ATP2A1 transcript and unable to
regulate exon 22 inclusion, resulting in very low inclusion
and an aberrant transcript (32). As expected, when our
minigene is spliced in the presence of 960 CUG repeats,
the inclusion of exon 22 drops to 2% (Figure 7B, lane 3).
Importantly, splicing of the ATP2A1 reporter in combi-
nation with over-expression of MBNL1 lead to an
increase in exon 22 inclusion to 74% (Figure 7B, lane 5
and 7D). In combination, these observations suggest that
our ATP2A1 minigene is a good reporter and is amenable
to studying MBNL1-mediated splicing eﬀects in a
DM1-related transcript.
Multiple YGCY motifs are found in the intron down-
stream of ATP2A1 exon 22. We demonstrated that
MBNL1 binds to an RNA oligonucleotide derived from
this region (Figure 6B), making this site a candidate for an
endogenous MBNL1-binding site responsible for regula-
tion of exon 22. To test the importance of this site and the
surrounding YGCY motifs on splicing regulation we
deleted 151nt of intron 22 in the splicing minigene to
create an ATP2A1 deletion minigene (ATP2A1 DEL)
that lacks both the high-aﬃnity ATP2A1-binding site
and six YGCY motifs located downstream of the
ATP2A1 site (Figure 7C). When the ATP2A1 DEL
minigene was tested under the same splicing conditions
as the WT ATP2A1 minigene we observed that deletion
of the high-aﬃnity site lead to a decrease in exon 22 inclu-
sion from 22 to 5% (Figure 7C, compare lane 7 to lane 1).
This observation could imply that removal of the
high-aﬃnity site created a minigene that endogenous
MBNL1 recognizes much less eﬃciently. Alternatively
this decrease to 5% inclusion could be due to the loss of
intronic enhancer elements that operate independently of
MBNL1. Inclusion of exon 22 of the ATP2A1 DEL
minigene was also reduced to 2% upon co-expression of
CUG repeats (Figure 7B, lane 9). This is an important
observation because it implies that although
A
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Figure 7. Evaluation of MBNL1 recognition of YGCY motifs in an
endogenous target, ATP2A1. (A) Diagram of the ATP2A1 minigene,
with white boxes indicating exons 21 and 23, lines to represent
intervening introns, and a gray box representing the alternatively
spliced exon 22, the inclusion of which is regulated by MBNL1.
Sequence of intron 22 is shown with high-aﬃnity MBNL1-binding
site (ATP2A1-binding site) underlined. The intronic sequence contained
within the red brackets indicates the portion of the intron (151nt) that
was deleted to create the ATP2A1 deletion (ATP2A1 DEL) minigene in
B. Capitalized nucleotides represent exonic sequence, lower case
nucleotides represent intronic sequence. YGCY motifs contained
within the deletion region are in bold. (B) HeLa cells were transfected
with either ATP2A1 WT or ATP2A1 DEL splicing reporter minigenes
alone, or with either MBNL (+MBNL) or DMPK-CUG960 (+CUG)
co-expression. Splice products are diagramed. The top band corre-
sponds to the splice product containing exon 22 (gray box), whereas
the bottom band corresponds to the splice product wherein exon 22 is
excluded. The resulting splicing products were quantiﬁed using
radiolabeled RT-PCR and percent exon 22 inclusion is reported
below representative acrylamide gels. The values reported are an
average of at least four independent experiments. (C) Sequence of
intron 22 after the 151nt deletion (red bracketed DEL). Target
sequences of ASOs boxed and YGCY motifs contained within the
ATP2A1 DEL minigene are indicated in bold. (D) HeLa cells were
transfected with the ATP2A1 DEL minigene in combination with the
ASOs diagrammed in C, both with (gray columns) or without (white
columns) MBNL co-expression, and the percentage of exon 22 was
quantiﬁed as in B. Inclusion values reported are the result of at least
three independent experiments.
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minigene is impaired signiﬁcantly, it isn’t completely
eliminated because MBNL1 sequestration is still capable
of reducing the inclusion ratio slightly. Following this line
of reasoning, splicing of the ATP2A1 DEL minigene in
combination with over-expression of MBNL1 caused exon
22 inclusion to increase to 26% (Figure 7B, lane 11). This
observation also suggests that the deletion was successful
in reducing the MBNL1-mediated splicing eﬀects of the
ATP2A1 minigene, but did not eliminate MBNL1’s ability
to regulate exon 22 inclusion. Taken together, these
ﬁndings imply that deletion of the high-aﬃnity ATP2A1
site from intron 22 of the minigene is not suﬃcient to
eliminate all of the functional MBNL1-binding sites in
the ATP2A1 transcript.
Upon further examination of the ATP2A1 DEL
minigene, we observed two remaining regions of intron
22 containing clusters of YGCY motifs (Figure 7C). If
these potential MBNL1-binding sites are functional in reg-
ulation of the ATP2A1 transcript, then they may be
responsible for maintaining MBNL1-mediated regulation
of exon 22 in the context of the deletion. Next, we used
ASO (Figure 7C) to block the remaining motifs
(see ‘Materials and Methods’ section) in combination
with the deletion to determine if removing additional
YCGY motifs is suﬃcient to completely eliminate
MBNL1-mediated splicing eﬀects on ATP2A1 exon 22.
ASOs have previously been shown to aﬀect splicing
in vitro and in tissue culture (34,35). Splicing of the
ATP2A1 DEL minigene in the presence of each ASO
was evaluated both with and without co-expression of
MBNL1 and percentage of exon 22 inclusion was
quantiﬁed (Figure 7D). ASO1 was designed as a control
to show that blocking the 50splice site of the intron with an
ASO directed against that region is suﬃcient to block the
splicing machinery from recognizing the 50 splice site,
leading to a robust change in the splicing pattern of the
minigene that is independent of MBNL1 over-expression.
As expected, blocking the 50 splice site with ASO1 resulted
in a reduction in exon 22 inclusion to 2%, an eﬀect that
was MBNL1 independent (Figure 7D). ASO3 was
designed as a control to show that not all ASO binding
events alter splicing regulation. In the context of ATP2A1
DEL minigene and MBNL1 over-expression, ASO3 had
little eﬀect on MBNL1’s ability to regulate exon 22 inclu-
sion (Figure 7D).
ASO2 targets a section of the ATP2A1 DEL that
contains four YGCY motifs (Figure 7C) and is a logical
candidate for an endogenous MBNL1-recognition site
because it is located within the 50 end of the intron, near
the alternatively regulated 50 splice junction. Blocking the
potential MBNL1-binding site of the ATP2A1 DEL
minigene with ASO2 caused a decrease in exon 22 inclu-
sion to 4% (Figure 7D). Interestingly, over-expression of
MBNL1 in combination with ASO2 treatment showed no
signiﬁcant increase in exon 22 inclusion. This observation
suggests that blocking the four YCGY motifs immediately
downstream of the 50 splice junction via ASO2 is suﬃcient
to eliminate MBNL1-mediated regulation of ATP2A1
exon 22 in the context of the deletion.
Finally, ASO4 was designed to a region at the 30 end of
the intron that also contains four YGCY motifs and is
therefore another potential MBNL1-binding site. ASO4
treatment in combination with ATP2A1 DEL reduced
exon 22 inclusion to 3%, similar to the eﬀect observed
upon ASO2 treatment. Although ASO4 treatment alone
is capable of suppressing the ATP2A1 DEL minigene
further than the deletion alone, in combination with
over-expression of MBNL1, the inclusion was increased
to 15% (Figure 7D). This observation suggests that
blocking these four YGCY motifs found in ASO4 is not
suﬃcient to eliminate MBNL1’s ability to regulate the
inclusion of this exon. Not surprisingly however, when
the ATP2A1 DEL minigene is spliced with ASO2 in com-
bination with ASO4 the amount of exon 22 inclusion was
decreased to 4%. When this minigene is subjected to
splicing with ASO2, ASO4 and MBNL1 over-expression,
no signiﬁcant change in exon inclusion is observed.
Therefore, the decrease in exon 22 inclusion with the com-
bination of ASO2 and ASO4 is MBNL1-independent,
suggesting that the combination of ASO2 and ASO4 is
also suﬃcient to completely eliminate MBNL1-mediated
regulation of ATP2A1 exon 22 in the context of the
deletion.
These experiments indicate that the ATP2A1 tran-
script, an endogenous target of MBNL1, contains
multiple functional and, potentially high-aﬃnity,
MBNL1-binding sites. It is important to note that in
this particular case, simply eliminating one YGCY motif
or high-aﬃnity binding site is not suﬃcient to eliminate
MBNL1-mediated splicing eﬀects. Rather, multiple
YGCY motifs, spanning much of the regulated intron,
must be removed or blocked to fully remove MBNL1
regulation.
YGCY motifs are enriched in the intronic regions ﬂanking
DM1 mis-spliced exons
To identify new MBNL1 sites, we analyzed the intronic
regions encompassing 24 human exons known to be
mis-spliced in DM1 (for literature references see
Supplementary Table S2). We identiﬁed the locations of
all instances of YGCY within the last 200nt of the
upstream intron and the ﬁrst 200nt of the downstream
intron (if either intron was <400nt in length only half of
the intron was included) (Figure 8A). Although we do not
know if MBNL1 directly regulates the splicing of all of
these exons, all 24 of these exons have one or more
instances of YGCY in the adjacent intronic sequences
and several contain instances within the exon as well.
Considering both the small size and the degeneracy of
this motif this observation by itself is not surprising. We
carried out several statistical tests to determine if there is a
signiﬁcant correlation between the occurrence of the
YGCY motif within these regions and the mis-regulation
of splicing in DM1.
A correlation between binding-site location and
enhancer or silencer activity has been observed for
several alternative splicing regulators such as NOVA1
and A2BP1 (4,5). In order to determine if a similar corre-
lation is observed for instances of YGCY and DM1
Nucleic Acids Research,2010, Vol.38, No. 7 2479related mis-regulation, we evaluated the association
between the frequency of YGCY in the upstream
(acceptor) and downstream (donor) intronic ﬂanks
versus the type of mis-splicing seen in DM1. We
observed that, if the exon is included (represented by an
I in Figure 8A) in normal individuals (excluded in DM1),
occurrences of YGCY are biased toward the donor region
(Figure 8B). Conversely, if the exon is excluded (repre-
sented by an E in Figure 8A) in normal individuals, the
motifs are biased toward the acceptor side (Figure 8B).
The chi-squared test for association conﬁrmed the signif-
icance of this bias within this dataset (P=7.4 10
–7).
In order to determine whether or not YGCY motifs are
enriched within these regions relative to human intronic
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Figure 8. (A) Schematic representation of exons and ﬂanking regions that are mis-spliced in DM1 with instances of YGCY motifs. Two hundred
bases (unless the intron is <400 bases, then only half of the intron was used) upstream and downstream of the mis-spliced exon are represented for
each gene. All regions are drawn to scale. Exons are indicated as boxes and introns as lines. The gene names are those that appear in the UCSC
genome browser (http://genome.ucsc.edu/). The ‘I’ or ‘E’ after each gene indicates that the exon is generally included or excluded in normal
individuals (according to literature references, Supplementary Table S2). The smaller open boxes denote YGCY motifs. The ﬁlled boxes indicate
YGCY motifs that are within regions tested for binding to MBNL1 in Figure 6. (B) YGCY motifs are enriched in the upstream acceptor ﬂank of
exons that are normally excluded and are enriched in the downstream donor ﬂanks of exons that are normally included. The bars indicate the
frequency of YGCY motifs in the upstream (acceptor) intronic ﬂanks and downstream (donor) intronic ﬂanks for the exons shown in A. For each
bar, the background frequency for YGCY is indicated as a solid line. The upper and lower dashed lines represent the upper and lower 99%
conﬁdence intervals that deﬁne the range of frequencies expected if the same number of intronic ﬂanks were randomly drawn from the population of
all intronic ﬂanks. These were calculated as described in the ‘Materials and Methods’ section. (C) Model of how MBNL1 binding correlates to exon
regulation. When MBNL1 binds upstream of an alternatively spliced exon, MBNL1 suppresses inclusion of that exon. Conversely, when MBNL1
binds downstream of an alternatively spliced exon, MBNL1 enhances exon inclusion.
2480 Nucleic Acids Research, 2010,Vol.38, No. 7ﬂanks in general, we determined the background fre-
quency of YGCY within the corresponding regions of
all human intronic ﬂanks (solid line, Figure 8B) and
then calculated a 99% conﬁdence interval for the range
of frequencies of YGCY expected within sample sizes
equivalent to those used in this analysis (dashed lines,
Figure 8B, and ‘Materials and Methods’ section). This
test revealed that, despite the small size and degeneracy
of the putative MBNL1-binding site and the small sample
size of putative MBNL1 regulated exons currently avail-
able, YGCY is signiﬁcantly enriched above background
levels in the acceptor intronic ﬂanks of exons that are
excluded in normal individuals and in the donor intronic
ﬂanks of exons that are normally included (Figure 8B).
Meanwhile the frequency of YGCY in the alternate
ﬂank is essentially the level expected by chance. To
further demonstrate that this association is a phenomenon
of YGCY, we performed identical analysis using several
motifs similar to YGCY but which contain speciﬁc sub-
stitutions: YGUY, YCGY and RGCR (Supplementary
Figure S2). We observed that, of the motifs tested, only
YGCY shows a signiﬁcant and biased enrichment
correlated with the inclusion/exclusion of the adjacent
exon.
AlthoughYGCYmotifsareoftenlocatedbothupstream
and downstream of regulated exons (Figure 8A) it is likely
that only subsets of these are functionally relevant
MBNL1-binding sites. Additional features that we have
not yet fully explored are likely to play important roles
in creating physiologically functional sites, such as
pyrimidine content and structure. However, the data pre-
sented here supports the model that MBNL1-binding
upstream of an exon is likely to cause silencing of the
downstream splice site while MBNL1-binding down-
stream of an exon is likely to enhance usage of the
upstream splice site (Figure 8C).
DISCUSSION
The data presented here have provided insights into
MBNL1’s RNA-binding speciﬁcity. The SELEX experi-
ment recovered many RNAs that bind MBNL1 with
high aﬃnity. Analysis of the selected RNAs suggests
that MBNL1 has an overall preference for pyrimidines
and requires the motif YGCY for high-aﬃnity binding.
This motif is quite similar to the previously reported
motif of YGCU
U/GY, which was identiﬁed by comparing
four MBNL1-binding sites, two in chicken TNNT2 and
two in human TNNT2 (24). All nine RNAs that MBNL1
has been shown to bind, including CUG repeats, chicken
and human TNNT2, mouse Atp2a1, mouse Tnnt3 and the
four new putative sites identiﬁed in this study (those with
Kds<50nM are being considered putative sites), have the
common motif of YGCY (Figure 6). The analysis of
nucleotide frequencies of regions ﬂanking GC dimers
suggests the Y positions in YGCY have a strong bias
toward uridine (Figure 2C). Interestingly, the four
known MBNL1-binding sites (human and chicken
TNNT2, mouse Atp2a1 and mouse Tnnt3, Figure 6A)
all contain multiple CGCU, UGCU or UGCU motifs
and do not contain any CGCC motifs. GRIN1 is the
only RNA in Figure 6A that contains CGCC and it
binds MBNL1 with lower aﬃnity (Figure 6A). In
addition, our work on MBNL1-dependent PLEKHH2
minigene reporter splicing indicates that MBNL1
requires at least one U in either Y position in the
YGCY motif to regulate splicing (Figure 5). The CCUG
repeats have also been shown to be high-aﬃnity binding
sites for MBNL1 (7,15) and the common motif in these
repeats is UGCC not CGCC (Figure 6A). Taken together,
these results strongly suggest that MBNL1 requires
multiple GC steps ﬂanked by at least one U and a
pyrimidine on the opposite ﬂank.
Several lines of evidence suggest that local pyrimidine
content inﬂuences MBNL1 binding: (i) this SELEX exper-
iment demonstrated overall selection for uridines; (ii) the
native TNNT2-binding site and most of the high-aﬃnity
sites adjacent to regulated exons (this study) are generally
pyrimidine rich; (iii) CUG and CCUG repeat RNAs are
highly pyrimidine rich; and (iv) The sequences inserted in
PLEKHH2-SM1F, PLEKHH2-SM2 and PLEKHH2-
SM3 that confer MBNL1-splicing regulation are 83%
pyrimidine. The mouse Tnnt3 and the mouse Atp2a1
sites contain lower levels of pyrimidines in general
compared to the other known MBNL1-binding sites
(Figure 6). However, the regions of these transcripts
proposed to bind MBNL1 (an 18nt stem-loop and two
YGCY motifs within 12nt of each other, respectively)
contain higher levels of pyrimidines (33,36). In other
words, for these speciﬁc transcripts the regions of the tran-
scripts proposed to contain an MBNL1-binding site have
higher, local pyrimidine content than the overall tran-
script. Therefore, when only these regions of the tran-
scripts are considered the mouse Tnnt3 and the mouse
Atp2a1 transcripts are similar in pyrimidine composition
to the other sites. This supports the model that MBNL1
prefers to bind YGCY motifs when they are embedded
within pyrimidines. The GRIN1 and INSR RNAs bind
more weakly to MBNL1 compared to the other RNAs,
and, interestingly, both of these RNAs contain a lower
pyrimidine content compared to the other RNAs (Figure
6). This observation also supports the model that
high-aﬃnity MBNL1-binding sites will be found within
pyrimidine-rich sequences. Although MBNL1 bound the
GRIN1 and INSR sites more weakly, it is still possible
that MBNL1 interacts with these sites and regulates
splicing through them, especially if other protein factors
enhance the binding of MBNL1 to these sites.
Another commonality among the RNAs that MBNL1
binds with high aﬃnity is that they contain multiple
YGCY motifs. A signiﬁcant fraction of the SELEX
RNAs contains two or more YGCY motifs (Figure 3).
The CUG repeats, CCUG repeats, TNNT2, ATP2A1
and several potential MBNL1 sites identiﬁed in this
study also contain multiple copies of the YGCY motif.
These results suggest that high-aﬃnity MBNL1 sites will
be both pyrimidine rich and contain multiple copies of the
YGCY motif. It will be important to follow up the iden-
tiﬁcation of these putative new MBNL1 sites with func-
tional studies to determine if the YGCY motifs
regulate the splicing of these exons and if their eﬀect on
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MBNL1 dependent. We showed that in the case of
ATP2A1 exon 22 regulation, MBNL1 utilizes multiple
YGCY motifs, spanning a large portion of intron 22 for
proper splicing regulation. This ﬁnding is in agreement
with the model that MBNL1 requires multiple YGCY
motifs for binding and splicing regulation.
MBNL1 has been shown to bind to several diﬀerent
types of RNA targets. The ﬁrst type is the toxic CUG
and CCUG repeat RNA (12,15), speciﬁcally the
expanded CUG and CCUG repeats which form long,
A-form stem-loops containing pyrimidine–pyrimidine
mismatches in between G-C and C-G base pairs (37–40).
Similarly, MBNL1’s binding sites in TNNT2 and mouse
Tnnt3 pre-mRNAs are stem-loops containing pyrimidine–
pyrimidine mismatches (7,36), suggesting MBNL1 is
recognizing all of these sites through a common mode of
recognition. A recent crystal structure of Zn ﬁngers 3–4
from human MBNL1 in complex with a 6-mer RNA (CG
CUGU) shows that the GC core of the YGCY motif is
recognized via its Watson–Crick face, indicating that the
GC core is not able to simultaneously bind MBNL1 and
form Watson–Crick base-pairs in a stem-loop structure
(17). This structure, in combination with the data pres-
ented here showing that MBNL1 prefers YGCY motifs
embedded in pyrimidine-rich RNAs, suggests MBNL1
binds this motif when it is partially or fully unfolded.
It is possible that RNA structure in the remainder of the
RNA enhances binding to MBNL1. A similar combina-
tion of primary sequence and secondary structure has
been shown to be important for NOVA1 binding in
which its site can be presented in the loop portion of a
stem-loop (41).
We used Sfold (website: http://sfold.wadsworth.org) to
predict structures of the six potential MBNL1-binding
sites identiﬁed in this study (40–45nt) (data not shown)
(42,43). Interestingly, there is a mix of strong stem-loops
and weaker stem-loops and no strong correlation between
MBNL1’s binding aﬃnity and the stability of the pre-
dicted structure. The analysis of the RNAs from the
SELEX using Sfold also did not indicate a correlation
between predicted RNA structure and MBNL1 binding.
It does not appear that within this set of RNAs, a speciﬁc
RNA structure is required for MBNL1 binding. Structure
may be one aspect inﬂuencing how MBNL1 regulates
splicing and another inﬂuence could be binding site
location.
The creation of the ﬁrst ‘synthetic’ MBNL1 regulated
exon (PLEKHH2-SM1F) demonstrates that six copies of
the motif (CUGCUU) are all that is necessary and suﬃ-
cient for MBNL1 to block inclusion of an exon. The
minigene containing the reverse of the motif in
PLEKHH2-SMIF (PLEKHH2-SM1R) shows that the
GC core is critical for this control by MBNL1
(Figure 5). We chose to place the MBNL1 motifs 10nt
upstream of the putative branch site and poly-pyrimidine
tract in intron 20 so as to avoid direct steric competition
with the splicing factors recognizing these elements. This
region upstream of the 30 splice site has been shown by
us and others to frequently contain splicing enhancers
and repressors (29,44). Therefore, we felt this was an
appropriate location for placement of the six CUGCUU
motifs. It is likely that MBNL1 is repressing the use of the
PLEKHH2-SM1F 30 splice site through a diﬀerent mech-
anism than the blocking of U2AF65 binding at the
poly-pyrimidine tract, which is how MBNL1 negatively
regulates exon 5 of the TNNT2 pre-mRNA (25). In the
future it will be interesting to determine the multiple
mechanisms through which MBNL1 acts to negatively
and positively regulate splicing.
Multiple alternative splicing regulators have been
shown to have positional biases with respect to where
their binding site is relative to the regulated exon. For
example, A2BP1 has been shown to function as a
repressor when bound upstream of a regulated exon and
as an enhancer when bound downstream (4). NOVA and
the CELF family of proteins have also been shown to have
a position-dependent mode of splicing regulation (2,5).
Although there has not been a comprehensive analysis
of MBNL1-binding sites, several pieces of evidence
suggest MBNL1 may share common splicing mechanisms
with these other factors. The characterization of
MBNL1’s binding site in TNNT2 conﬁrms that MBNL1
acts as a repressor when binding upstream of exon 5
(7,24). In addition, the presence of a branch point
sequence and a poly-pyrimidine tract near the MBNL1
site suggests that MBNL1 blocks recognition of those
sequences by inhibiting the binding of the splicing factor
U2AF65 (25). In the case of the PLEKHH2 transcript,
placing MBNL1-binding sites upstream of exon 21 also
causes MBNL1-dependent repression of exon 21, similar
to how MBNL1 regulates TNNT2 exon 5 splicing
(Figure 5). In regards to positive regulation, YGCY sites
downstream of exon 22 in the human ATP2A1
pre-mRNA function as positive regulators of exon inclu-
sion through MBNL1 binding (Figure 7). And ﬁnally, sta-
tistical analysis of introns ﬂanking DM1 mis-spliced exons
revealed that YGCY sites are enriched upstream of exons
that are normally excluded (relative to DM levels) and are
enriched downstream of exons that are normally included
(relative to DM levels). These results support the model
(Figure 8C) that MBNL1 acts as a negative regulator
when bound upstream of a regulated exon and as a
positive regulator when bound downstream.
Identiﬁcation of additional MBNL1-binding sites in
pre-mRNA targets will be very useful toward understand-
ing MBNL1’s alternative splicing mechanisms and to
identify the full list of pre-mRNA targets MBNL1 regu-
lates. However, with a potential structural aspect as well
as the sequence aspects, MBNL1’s binding sites may be
degenerate and challenging to recognize in a sea of
intronic sequence. This doped SELEX has provided a
useful set of criteria for identifying potential
MBNL1-binding sites; YGCY motifs embedded in
pyrimidines. We have shown that sites created (in the
case of PLEKHH2 reporters) or identiﬁed (in the case of
ATP2A1) using these criteria have proven to be suﬃcient
for MBNL1-dependent splicing regulation. In the future
these criteria will aid in the identiﬁcation of additional
MBNL1 targets and currently has furthered the under-
standing of MBNL1’s mode of splicing regulation.
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